
zzso zzso zzso zzso caused by zzso zzso zzso zzso has been reported, but the zzso optimal dose, and schedule remain zzso zzso a phase I and zzso study of zzso with escalating doses of zzso was zzso 

zzso zzso zzso was given by continuous intravenous zzso infusion for 5 zzso zzso zzso to 15 zzso zzso zzso was given zzso zzso daily for 5 days concurrent with zzso Courses were repeated every 14 to 21 zzso zzso patients were zzso 39 received at least two zzso During the first course of therapy, zzso levels before and after administration of zzso were zzso in 26 patients by zzso liquid zzso 

The zzso dose of zzso was 10 zzso zzso zzso zzso was zzso Three partial and five minor responses zzso zzso zzso showed that zzso did not alter zzso plasma concentration zzso range, zzso zzso zzso zzso to zzso zzso zzso zzso elimination zzso zzso mean, zzso zzso zzso zzso area under the zzso curve zzso range, 93 to 224 zzso zzso hours), zzso clearance zzso range, zzso to zzso zzso or volume of distribution zzso zzso to zzso zzso of zzso zzso data evaluation revealed a zzso effect of zzso The mean zzso zzso after zzso administration zzso zzso was greater than that before zzso administration zzso zzso P zzso zzso zzso zzso after zzso administration was reduced by zzso to zzso compared with use of zzso alone zzso zzso zzso Patients with a greater than zzso decrease in zzso zzso had a fourfold greater zzso of zzso 

zzso reduces zzso zzso and, consequently, increases zzso zzso Phase II studies of zzso and zzso seem to be zzso 

